medigraphic.com
ISSN 1561-2937 (Impreso)

2021, Número 2

<< Anterior Siguiente >>

Rev Cubana Cardiol Cir Cardiovasc 2021; 27 (2)


Detección de dislipoproteinemias primarias en pacientes con enfermedad arterial coronaria prematura

García GY, Cobas CL, Guevara MG, Martínez CA, Borges MY, Ortega TY

Idioma: Español
Referencias bibliográficas: 42
Paginas:
Archivo PDF: 296.26 Kb.


FRAGMENTO

Las dislipoproteinemias constituyen un importante factor de riesgo de las enfermedades cardiovasculares, las cuales constituyen la principal causa de muerte en la mayoría de los países desarrollados y en vías de desarrollo. Se caracterizan por alteraciones cuantivativas y/o cualitativas en las diferentes fracciones lipídicas y lipoproteínas del plasma. Entre ellas, las dislipoproteinemias primarias (DLPP) constituyen un grupo heterogéneo de alteraciones lipídicas con una base genética más específica y mejor conocida.
El enfoque tradicional de las dislipoproteinemias como factor de riesgo cardiovascular, sin delimitar a los pacientes afectados por una causa primaria, genera subestimación del riesgo y un manejo inadecuado de los mismos. En ellos, se asume un mayor tiempo de exposición al riesgo desde la infancia y un perfil lipídico más grave que genera un incremento de la “carga aterosclerótica” a largo plazo. Estos pacientes tienen alto riesgo cardiovascular y por tanto, no requieren de evaluación a través de las funciones de riesgo tradicionales, las cuales sí serían útiles en otros pacientes con dislipoproteinemias.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Kersten S. The Genetics of Dyslipidemia- When Less Is More. N Engl J Med.2016;374:1192-93. DOI: 10.1056/NEJMe1601117

  2. Sharifi M, Higginson E, Bos S, Gallivan A, Harvey D, Li KW, et al. Greater preclinical atherosclerosis in treated monogenic familial hypercholesterolemia vs. polygenic hypercholesterolemia. Atherosclerosis.2017;263:405-11. DOI: http://dx.doi.org/10.1016/j.atherosclerosis.2017.05.015

  3. Bucholz EM, Rodday AM, Kolor K, Khoury MJ, de Ferranti SD. Prevalence and predictors of cholesterol screening, awareness, and statin treatment among US adults with familial hypercholesterolemia or other forms of severe dyslipidemia (1999–2014). Circulation.2018;137:00-00. DOI: 10.1161/CIRCULATIONAHA.117.032321

  4. Garg A, Garg V, Hegele RA, Lewis GF. Practical definitions of severe versus familial hypercholesterolaemia and hypertriglyceridaemia for adult clinical practice. Lancet Diab Endocrinol. 2019;7(11):880-86. DOI: http://dx.doi.org/10.1016/S2213-8587(19)30156-1

  5. Benn M, Watts GF, Tybjærg-Hansen A, Nordestgaard BG. Mutations causative of familial hypercholesterolaemia: screening of 98 098 in dividuals from the Copenhagen General Population Study estimated a prevalence of 1 in 217. Eur Heart J.2016;37:1384-94. DOI: 10.1093/eurheartj/ehw028

  6. Pereira E, Ferreira R, Hermelin B, Thomas G, Bernard C, Nassiff H, et al. Recurrent and novel LDL receptor gene mutations causing heterozygous familial hypercholesterolemia in La Habana. Hum Genet. 1995;96(3):319-22. DOI: 10.1007/BF00210415.

  7. Akioyamen LE, Genest J, Shan SD, Reel RL, Albaum JM, Chu A, et al. Estimating the prevalence of heterozygous familial hypercholesterolaemia: a systematic review and meta-analysis. BMJ Open.2017;7:161-69. DOI:10.1136/bmjopen-2017-016461

  8. Nordestgaard BG, Chapman MJ, Humphries SE, Ginsberg HN, Masana L, Descamps OS, et al. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society. Eur Heart J. 2013; 34:3478-90. DOI:10.1093/eurheartj/eht273

  9. Beheshti SA, Madsen CM, Varbo A, Nordestgaard BG. Worldwide Prevalence of Familial Hypercholesterolemia Meta-Analyses of 11 Million Subjects. J Am Coll Cardiol.2020;75:2553-66. DOI: https://doi.org/10.1016/j.jacc.2020.03.057

  10. Rosso A, Pitini E, Andrea ED, Massimi A, De Vito C, Marzuillo C, et al. The cost-effectiveness of screening for familial hypercholesterolemia: a systematic rewiew. Ann Ig.2017;29:464-80. DOI: 10.7416/ai.2017.2178

  11. Vallejo-Vaz AJ, De Marcoa M, Stevens CAT, Akramb A, FreibergerT, Hovinghe GK, et al. Overview of the current status of familial hypercholesterolaemia care in over 60 countries - The EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC). Atherosclerosis.2018;277:234–55. DOI: https://doi.org/10.1016/j.atherosclerosis.2018.08.051

  12. Sturm AC, Knowles JW, Gidding SS, Ahmad ZS, Ahmed CD, Ballantyne CM, et al. Clinical genetic testing for familial hypercholesterolemia. JACC Scientific Expert Panel. J Am Col Cardiol. 2018;72:662-80. DOI: https://doi.org/10.1016/j.jacc.2018.05.044

  13. Aguilar-Salinas CA, Gómez-Díaz R, Tusió e-Luna MT. Fifty years studying hiperlipidemias: the case of familial combined hiperlipidemia. Invest. Clin.2010[citado 22 may 2020] ;51( 2 ):145-158. Disponible en: http://ve.scielo.org/scielo.php?script=sci_arttext&pid=S0535-51332010000200002&lng=es.

  14. Bello-Chavolla OY, Kuri-García A, Ríos-Ríos M, Vargas-Vázquez, Cortés-Arroyo JE, Tapia-González G, et al. Familial Combined Hyperlipidemia: Current Knowledge, Perspectives, and Controversies. Rev Invest Clin.2018;70:224-36. DOI: 10.24875/RIC.18002575

  15. Goldstein JL, Schrott HG, Hazzard WR, Bierman EL, Motulsky AG. Hyperlipidemia in coronary heart disease. II. Genetic analysis of lipid levels in 176 families and delineation of a new inherited disorder, combined hyperlipidemia. J Clin Invest.1973;52:1544-68. DOI: 10.1172/JCI107332

  16. Sniderman AD, de Graaf A, Thanassoulis G, Tremblay AJ, Martin SS, Couture P, et al. The spectrum of type III hyperlipoproteinemia. J Clin Lipidol.2018;12:1-7. DOI: https://doi.org/10.1016/j.jacl.2018.09.006

  17. Besseling J, Kindt I, Hof M, Kastelein JJP, Hutten BA, Hovingh GK. Severe heterozygous familial hypercholesterolemia and risk for cardiovascular disease: A study of a cohort of 14,000 mutation carriers. Atherosclerosis.2014;233:219-23. DOI: http://dx.doi.org/10.1016/j.atherosclerosis.2013.12.020

  18. Marks D, Thorogood M, Neil HAW. A review on the diagnosis, natural history, and treatment of familial hypercholesterolaemia. Atherosclerosis.2003;168 (1):1-14.

  19. Nanchen D, Gencer B, Auer R, Raber L, Stefanini GG, Klingenberg R. Prevalence and management of familial hypercholesterolaemia in patients with acute coronary syndromes. Eur Heart J.2015; 36:2438-45. DOI: doi:10.1093/eurheartj/ehv289

  20. Auckle R, Su B, Li H, Xu S, XieM, Song Y. Familial hypercholesterolemia in Chinese patients with premature ST-segment-elevation myocardial infarction: Prevalence, lipid management and 1-year follow-up. PLoS ONE.2017;12: e0186815. DOI: https://doi.org/10.1371/journal.pone.0186815

  21. Nanchen D, Gencer B, Muller O, Auer R, Aghlmandi S, Heg D. Prognosis of patients with familial hypercholesterolemia after acute coronary syndromes. Circulation.2016;134:698-709. DOI: 10.1161/CIRCULATIONAHA.116.023007

  22. Amor-Salamanca A, Castillo S, Gonzalez-Vioque E, Dominguez F, Quintana L, Ganella L, et al. Genetically Confirmed Familial Hypercholesterolemia in Patients with Acute Coronary Syndrome. J Am Coll Cardiol.2017;70:1732-40. DOI: 10.1016/j.jacc.2017.08.009.

  23. Rallidis LS, Kosmas N, Tsirebolos G, Rallidi M, Kiouri E, Kalpakos D. Prevalence of heterozygous familial hypercholesterolemia and combined hyperlipidemia phenotype in very young survivors of myocardial infarction and their association with the severity of atheromatous burden. J Clin Lipidol. 2019;13(3):502-08. DOI: https://doi.org/10.1016/j.jacl.2019.02.007

  24. De Backer G, Besseling J, Chapman J, Hovingh GK, Kastelein JJ, Kotseva K, et al. Prevalence and management of familial hypercholesterolaemia in coronary patients: An analysis of EUROASPIRE IV, a study of the European Society of Cardiology. Atherosclerosis.2015;241:169-75. DOI: http://dx.doi.org/10.1016/j.atherosclerosis.2015.04.809

  25. Behesht SO, Madsen CM, Varbo A, Nordestgaard BG. Worldwide Prevalence of Familial Hypercholesterolemia. Meta-Analyses of 11 Million Subjects. J Am Coll Cardiol.2020;75(20):2553-66. DOI: 10.1016/j.jacc.2020.03.057

  26. Al-Rasadi K, Al-Zakwani I, Alsheikh-Ali AA, Almahmeed W, Rashed W, Ridha M, Santos RD, et al. Prevalence, management and outcomes of familial hypercholesterolemia in patients with acute coronary syndromes in the Arabian Gulf. J Clin Lipidol.2018;134-41. DOI: https://doi.org/10.1016/j.jacl.2018.02.003

  27. Farnier M, Salignon-Vernay C, Yao H, Chague F, Brunel P, Maza M, et al. Prevalence, risk factor burden, and severity of coronary artery disease in patients with heterozygous familial hypercholesterolemia hospitalized for an acute myocardial infarction: Data from the French RICO survey. J Clin Lipidol.2019;13:1-7. DOI: https://doi.org/10.1016/j.jacl.2019.06.005

  28. Sawhney JPS, Ranjan S, Sharma M, Madan K, Mohanty A, Passey R, et al. Prevalence of familial hypercholesterolemia in premature coronary artery disease patients admitted to a tertiary care hospital in North India. Ind Heart J.2019;71(2):118-22. DOI: https://doi.org/10.1016/j.ihj.2018.12.004

  29. Do R, Stitziel NO, Won HH. Exome sequencing identifies rare LDLR and APOA5 alleles conferring risk for myocardial infarction. Nature.2015; 518:102-06. DOI: 10.1038/nature13917.

  30. Lee C, Cui Y, Song J, Li S, Zhang F, Wu M, et al. Effects of familial hypercholesterolemia-associated genes on the phenotype of premature myocardial infarction. Lip Health Dis.2019;18:95. DOI: 10.1186/s12944-019-1042-3.

  31. Cui Y, Li S, Zhang F, Song J, Lee C, Wu M, Chen H. Prevalence of familial hypercholesterolemia in patients with premature myocardial infarction. Clin Cardiol.2019;42:385-90. DOI: 10.1002/clc.23154

  32. Bogsrud MP, Øyri LKL, Halvorsen S, Atar D, Leren TP, Holven KB. Prevalence of genetically verified familial hypercholesterolemia among young (<45 years) Norwegian patients hospitalized with acute myocardial infarction. J Clin Lipidol.2020;14(3):339-45. DOI:https://doi.org/10.1016/j.jacl.2020.04.002

  33. Kramer AI, Trinder M, Brunham LR. Estimating the prevalence of familial hypercholesterolemia in acute coronary syndrome: a systematic review and meta-analysis. Can J Card.2019;35(10):1322-31. DOI: https://doi.org/10.1016/j.cjca.2019.06.017

  34. Khera AV, Won HH, Peloso GM, Lawson KS, Bartz TM, Deng X, et al. Diagnostic yield and clinical utility of sequencing familial hypercholesterolemia genes in patients with severe hypercholesterolemia. J Am Coll Cardiol.2016;67:2578-89. DOI: 10.1016/j.jacc.2016.03.520.

  35. Luijtena J, van Greevenbroekb MMJ, Schaper NC, Meexd SJR, van der Steena C, Meijer LJ, et al. Incidence of cardiovascular disease in familial combined hyperlipidemia: A 15-year follow-up study. Atherosclerosis.2019;280:1-6. DOI: https://doi.org/10.1016/j.atherosclerosis.2018.11.013

  36. Wiesbauer F, Blessberger H, Azar D, Goliasch G, Wagner O, Gerhold L, et al. Familial-combined hyperlipidaemia in very young myocardial infarction survivors (< or=40 years of age). Eur Heart J.2009;30:1073-79. DOI: doi:10.1093/eurheartj/ehp051

  37. Goldstein JL, Hazzard WR, Schrott HG, Bierman EL. Hyperlipidemia in coronary heart disease. Lipid levels in 500 survivors of myocardial infarction. J Clin Invest.1973;52:1573-43. DOI: 10.1172/JCI107331

  38. Koopal C, Retterstol K, Sjouke B, et al. Vascular risk factors, vascular disease, lipids and lipid targets in patients with familial dysbetalipoproteinemia: a European cross-sectional study. Atherosclerosis.2015;240(1):90-97. DOI: 10.1016/j.atherosclerosis.2015.02.046

  39. Al-Rasadi K, Al-Zakwani I. Use of Cardiovascular Risk Scores in Acute Coronary Syndrome Patients with Familial Hypercholesterolemia. J Clin Lipidol.2018. DOI: 10.1016/j.jacl.2018.07.001

  40. Barroso Leyva I, Bosch Alonso JR, Rodríguez Ramírez VR, Celorrio Fernández R, Peña García Y. Caracterización de pacientes menores de 65 años con infarto agudo del miocardio en terapia intensiva. Rev Cubana Cardiol [Internet].2019[citado 22/02/2020];25(4).Disponible en: http://www.revcardiologia.sld.cu/index.php/revcardiologia/article/view/854/pdf_1

  41. Estévez Rubido Y, Cairo Sáez G, Quintero Valdivié I, Pérez Rodríguez RM, González López D. Infarto agudo de miocardio en pacientes menores de 50 años en el Hospital Arnaldo Milián Castro. Rev Cubana Cardiol [Internet].2018[citado 22/02/2020];24(1):67-78. Disponible en: http://www.revcardiologia.sld.cu/index.php/revcardiologia/article/view/732/pdf_117

  42. Martín Torres RA, García Salas EA, Peña Oliva S. Caracterización del infarto agudo de miocardio en pacientes entre 45 y 59 años de edad. Rev Cubana Cardiol [Internet].2019[citado 22/02/2020]; 25(4). Disponible en: http://www.revcardiologia.sld.cu/index.php/revcardiologia/article/view/853/pdf




2020     |     www.medigraphic.com